| CAS NO: | 2159103-66-7 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 生物活性 | Navocaftor (GLPG 3067), as a cystic fibrosis transmembrane regulator (CFTR), is a protein modulator (US 20200377491 Al, example 1)[1]. | ||||||||||||
| IC50& Target | CFTR[1] | ||||||||||||
| 体外研究 (In Vitro) | Navocaftor, as a cystic fibrosis transmembrane regulator (CFTR), is a protein modulator[1]. | ||||||||||||
| Clinical Trial | |||||||||||||
| 分子量 | 416.33 | ||||||||||||
| 性状 | Solid | ||||||||||||
| Formula | C15H11F3N4O5S | ||||||||||||
| CAS 号 | 2159103-66-7 | ||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| 储存方式 |
| ||||||||||||
| 溶解性数据 | In Vitro: DMSO :< 1 mg/mL (ultrasonic)(insoluble or slightly soluble) In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
